论文部分内容阅读
目的探讨多参数流式细胞术(MFC)监测多发性骨髓瘤(MM)缓解期内微小残留病灶(MRD)的方法。方法采用MFC,利用CD45PE-cy5/SS设门,完成61例MM患者和8例正常人初次免疫分型。另有13例治疗后的MM患者,根据其初次免疫表型结果选择指标进行MRD动态监测。结果61例MM中骨髓瘤相关免疫表型(MAIP)的出现频率为:CD138+/CD38/CD56+(81.9%)、CD138+/CD38/CD19-(96.7%)、CD138+CD38/CD33+(21.3%)、CD138+/CD38/CD13+(11.4%)、CD138+/CD38/CD20+(19.7%)。另13例治疗后的MM根据其初次免疫表型结果,选择组合CD38/CD56+/CD45dim/-、CD138+/CD19-/CD45dim/-进行了MRD检测,12例(92.3%)检测到大于1.0×10-4水平的MRD。结论MFC免疫表型分析对于MM的治疗评估和预后判断可提供客观的依据。
Objective To investigate the method of multi-parameter flow cytometry (MFC) for monitoring minimal residual disease (MRD) in multiple myeloma (MM) during remission. Methods The primary immunophenotyping was performed in 61 MM patients and 8 normal controls using MFC and CD45PE-cy5 / SS. Another 13 cases of MM patients after treatment, according to the results of their primary immunophenotyping indicators for MRD dynamic monitoring. Results The frequency of myeloma associated immunophenotype (MAIP) in 61 MM patients was as follows: CD138 + / CD38 / CD56 + (81.9%), CD138 + / CD38 / CD19- (96.7%), CD138 + CD38 / CD33 + CD138 + / CD38 / CD13 + (11.4%), CD138 + / CD38 / CD20 + (19.7%). According to the results of the first immunophenotyping, the other 13 patients with MM treated by MRD showed that the combination of CD38 / CD56 + / CD45dim / -, CD138 + / CD19- / CD45dim / - was detected in 12 cases (92.3% -4 level MRD. Conclusion MFC immunophenotyping provides an objective basis for the treatment evaluation and prognosis of MM.